Design Therapeutics may sell up to $200M in stock

DSGN's last reported sale price was $10.34 per share on November 3, 2026.

Available on EDGAR 11/04/2026 - 04:28 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Design Therapeutics, Inc. may offer and sell up to $200,000,000 of common stock under its sales agreement prospectus and this supplement, through Jefferies LLC as agent from time to time. The amount includes $66,330,496.30 of shares sold as of November 4, 2026.

Key Figures

Maximum aggregate common stock sales: Up to $200,000,000 Common stock sold: $66,330,496.30 Last reported sale price: $10.34 per share

3 metrics

Maximum aggregate common stock sales Up to $200,000,000 Inclusive of shares previously sold under the sales agreement prospectus

Common stock sold $66,330,496.30 Under the sales agreement prospectus as of November 4, 2026

Last reported sale price $10.34 per share November 3, 2026

Key Terms

Open Market Sale, sales agreement prospectus, prospectus supplement

3 terms

Open Market Sale regulatory

"entered into an Open Market Sale (the “Sale Agreement”)"

An open market sale is when a company or a shareholder sells shares through the regular stock market to any willing buyer, using ordinary exchange trading rather than private deals. It matters to investors because it increases the number of shares available and can push the price down or change ownership balance—think of it like someone putting extra items on a supermarket shelf for any shopper to buy, which can lower the item's price if supply suddenly grows.

sales agreement prospectus regulatory

"filed as part of our registration statement on Form S-3"

A sales agreement prospectus is the document a company files and provides to investors when it asks permission to sell new shares or other securities to the public through an ongoing arrangement with an underwriter or broker. It explains how sales will be executed, the limits and costs, and the potential impact on existing shareholders; think of it as a menu and rulebook that lets a company raise cash quickly while warning investors about possible dilution.

prospectus supplement regulatory

"This prospectus supplement is being filed to update, amend and supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Offering Details

ATM · Up to $200,000,000, inclusive of $66,330,496.30 sold under the sales agreement prospectus

Offering

Offering Type ATM

Securities Offered Common stock

Offering Amount Up to $200,000,000, inclusive of $66,330,496.30 sold under the sales agreement prospectus

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much DSGN common stock can be sold under the sales agreement?

Up to $200,000,000 of common stock may be offered and sold, inclusive of $66,330,496.30 sold under the sales agreement prospectus as of November 4, 2026. Jefferies LLC acts as agent for sales from time to time.

What was DSGN's last reported stock price?

The last reported sale price was $10.34 per share on November 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-287043

PROSPECTUS SUPPLEMENT

(To Prospectus dated May 16, 2025)

Up to $200,000,000

Common Stock

This prospectus supplement is being filed to update, amend and supplement certain information in the sales agreement prospectus filed with the Securities and Exchange Commission on May 7, 2025 and dated May 16, 2025 (the “sales agreement prospectus”), filed as part of our registration statement on Form S-3 (File No. 333-287043). This prospectus supplement should be read in conjunction with the sales agreement prospectus. This prospectus supplement is only intended to update, amend and supplement certain information in the sales agreement prospectus to the extent set forth herein. Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the sales agreement prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the sales agreement prospectus, and any future amendments or supplements thereto.

We have entered into an Open Market Sale Agreement^SM (the “Sale Agreement”), dated April 27, 2022, with Jefferies LLC (“Jefferies”) relating to the offer and sale of shares of our common stock from time to time through Jefferies acting as agent. Prior to the filing of this prospectus supplement, the sales agreement prospectus covered the offer and sale by us of up to $100,000,000 of shares of our common stock pursuant to the Sale Agreement. As of the date of this prospectus supplement, we have sold an aggregate of $66,330,496.30 of shares of our common stock pursuant to the sales agreement prospectus. After giving effect to this prospectus supplement, we may offer and sell up to $200,000,000 of shares of our common stock pursuant to the sales agreement prospectus and this prospectus supplement, inclusive of the $66,330,496.30 of shares of our common stock sold under the sales agreement prospectus as of the date of this prospectus supplement.

Our common stock is listed on the Nasdaq Global Select Market under the symbol “DSGN.” On November 3, 2026, the last reported sale price of our common stock on the Nasdaq Global Select Market was $10.34 per share.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of the sales agreement prospectus and under similar headings in the other documents that are incorporated by reference into the sales agreement prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if the sales agreement prospectus and this prospectus supplement are truthful or complete. Any representation to the contrary is a criminal offense.

Jefferies

The date of this prospectus supplement is November 4, 2026.